What LuxMed does

LuxMed Systems, Inc. is a Boston-based, privately held medical device company founded in 2019 that develops image-guided therapeutic ablation catheters with integrated proprietary optics for cardiac arrhythmia treatment. The company's lead product is an optically enabled radiofrequency ablation catheter that performs real-time optical tissue interrogation during ablation procedures, allowing electrophysiologists to assess tissue contact, viability, lesion formation, and lesion progression — and to detect gaps in treatment — for the first time during the procedure itself. A second product, an optically enabled pulsed field ablation (PFA) catheter, is in development to follow the RF platform. The technology is protected by 61 issued patents and 20+ pending applications, and has been clinically validated in first-in-man studies (presented at HRS 2019) and in extensive preclinical animal work.

The business model centers on hardware sales of therapeutic ablation catheters and associated equipment to hospital electrophysiology labs and academic cardiac arrhythmia treatment centers — specifically centers performing catheter ablation for atrial fibrillation, ventricular tachycardias, and other arrhythmias. However, the company is presently pre-commercial: the device is classified as an investigational device under US federal law, explicitly 'Not Available for Sale,' and distribution channels have not yet been established. Go-to-market engagement is currently limited to scientific channels — peer-reviewed publications, HRS conference posters (2015, 2016, 2019), and clinical research collaborations with four top-tier US academic EP centers: Massachusetts General Hospital (Dr. Jeremy Ruskin), Mount Sinai Health System (Dr. Vivek Reddy), Duke University Hospital (Dr. Jonathan Piccini), and the Texas Cardiac Arrhythmia Institute (Dr. Andrea Natale). All four principal investigators also sit on the company's Scientific Advisory Board.

LuxMed is led by Co-Founder, President & CEO Omar Amirana, MD (formerly SVP at Allied Minds, Partner at Oxford Bioscience Partners, and at EP Technologies, Cardima, and St. Jude Medical); Co-Founder & CTO Terry Ransbury (serial EP entrepreneur with 40+ patents and 600+ procedures); and Co-Founder, VP Strategy & Marketing Arun Jaganathan (most recently Director at Allied Minds, prior at Boston Scientific and Fletcher Spaght). Independent directors R. John Fletcher (founder of Fletcher Spaght, ex-Spectranetics Chairman through $2.2B Philips sale), Rick Randall (former CEO of Target Therapeutics and Innovasive Devices), and Reggie Groves (former CFO/COO of Stimwave, CEO of REVA Medical, VP/GM at Medtronic AF Solutions) supply deep medtech commercialization and exit experience. As of the available data, the only disclosed funding event is a $100,000 investment from MassVentures on 2025-05-16.

Name

LuxMed

Legal name

LuxMed Systems, Inc.

Website

https://luxmedsystems.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

LuxMed Systems is a Boston-based, pre-commercial medical device company developing optically enabled ablation catheters with real-time tissue interrogation for lesion and gap detection in cardiac arrhythmia treatment, serving hospital electrophysiology labs.

Ownership category

akta.pro rank

Product category

Cardiac Ablation Catheters

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Electrophysiology Mapping & Ablation Systems (HLAHAFAD)

akta.pro secondary industries

Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser) (HLAHADAC), Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence) (HLAHADAH)

Keywords

• Cardiac ablation catheters
• Optical tissue interrogation
• Electrophysiology devices
• Cardiac arrhythmia treatment
• Image-guided ablation

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: Pre-commercialization stage. The company has developed therapeutic ablation catheters for cardiac arrhythmia treatment but the device is currently investigational and not available for sale. Revenue model will involve selling ablation catheters and associated equipment to hospital electrophysiology labs.

Go-to-market motion1 record

Marketing channels2 records

Core offering

LuxMed develops image-guided therapeutic ablation catheters with proprietary integrated optics that enable real-time optical tissue interrogation during cardiac ablation procedures. The company's first product is an optically enabled radiofrequency ablation catheter providing real-time lesion and gap detection, followed by an optically enabled pulsed field ablation catheter in development. The device is currently investigational and not available for sale.

Product overview

LuxMed offers a unified product platform centered on image-guided therapeutic ablation catheters with integrated optical tissue interrogation technology. The core product is the optically enabled radiofrequency ablation catheter, which provides real-time lesion and gap detection during cardiac ablation procedures. A second product in development is the optically enabled pulsed field ablation (PFA) catheter (electroporation), which will follow the RF ablation product. Both products share the same proprietary optical technology platform enabling electrophysiologists to optically assess heart tissue composition, tissue contact, tissue viability, and lesion progression during procedures.

Differentiator

Problem solved

Functional benefit

Products and services

• Optically Enabled Radiofrequency Ablation Catheter Therapeutic radiofrequency ablation catheter with integrated proprietary optics that enables electrophysiologists to optically assess heart tissue composition, metabolic activity, tissue contact, tissue viability, lesion formation, and lesion progression in real time during the ablation procedure. Provides real-time lesion and gap detection to support complete ablation, improved clinical outcomes, faster procedure times, and reduced repeat ablations. Targeted at electrophysiologists performing catheter ablation for cardiac arrhythmias including atrial fibrillation and ventricular tachycardias.
• Optically Enabled Pulsed Field Ablation (PFA) Catheter Pulsed field ablation (electroporation) catheter incorporating the same optical tissue interrogation technology platform as the radiofrequency catheter, enabling real-time lesion assessment during PFA procedures for cardiac arrhythmias.

Quantifiable outcome

• Improved clinical outcomes through better tissue assessment during ablation
• +2 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature7 records

Partnerships

Four partnerships are on record, tiered core.

• Massachusetts General HospitalcoreStrategic or Co-development PartnerClinical trial site and research collaboration with Dr. Jeremy Ruskin, Founder and Director Emeritus of Cardiac Arrhythmia Service at MGH and Professor of Medicine at Harvard Medical School. Dr. Ruskin serves on LuxMed's Scientific Advisory Board.
• Mount Sinai Health SystemcoreStrategic or Co-development PartnerClinical trial site and research collaboration with Dr. Vivek Reddy, Director of Cardiac Arrhythmia Services for The Mount Sinai Hospital. Dr. Reddy serves on LuxMed's Scientific Advisory Board.
• Duke University HospitalcoreStrategic or Co-development PartnerClinical trial site and research collaboration with Dr. Jonathan P. Piccini, Director of the Cardiac Electrophysiology section at the Duke Heart Center. Dr. Piccini serves on LuxMed's Scientific Advisory Board.
• Texas Cardiac Arrhythmia Institute at St. David's Medical CentercoreStrategic or Co-development PartnerClinical collaboration with Dr. Andrea Natale, Executive Medical Director and world-recognized leader in electrophysiology. Dr. Natale serves on LuxMed's Scientific Advisory Board.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Others

• Boston Scientific: Broad incumbent with EP ablation portfolio including Rhythmia mapping and force-sensing catheters, plus the FARAPULSE PFA system. Directly comparable in cardiac EP ablation, and LuxMed's CEO previously worked at the predecessor EP Technologies.

Broad incumbents

• Medtronic: Major EP ablation incumbent with DiamondTemp RF catheter, PulseSelect PFA, and the Affera mapping/ablation platform acquired in 2022. Direct competitor in cardiac arrhythmia ablation with established hospital relationships.
• Biosense Webster (Johnson & Johnson): The dominant EP ablation franchise globally with Thermocool RF catheters and the CARTO 3 mapping system. Most directly comparable incumbent that LuxMed would need to displace or partner with for hospital EP lab adoption.
• Abbott: Inherited St. Jude Medical's EP portfolio (EnSite NavX, TactiCath, TactiFlex) after acquiring St. Jude. Major EP ablation incumbent; LuxMed's CTO previously worked at Ventritex, which was acquired by St. Jude Medical (now Abbott).

Emerging players

• Pulse Biosciences: Clinical-stage company developing irreversible electroporation (Nano-Pulse Stimulation) for cardiac ablation among other applications. Comparable as an emerging non-thermal ablation modality player targeting the same arrhythmia market.
• Adagio Medical: Developer of next-generation cryo-ablation catheters for atrial fibrillation and ventricular tachycardia, including the iCLAS cryoablation system. Comparable as a venture-backed EP ablation company targeting lesion-quality and procedure-time improvements.
• Galvanize Therapeutics: Developer of pulsed electric field and energy-based therapies including for cardiac arrhythmias. Comparable emerging player bringing novel ablation energy modalities into the EP market.

Direct peers

• CardioFocus: Developer of the HeartLight balloon-based laser ablation catheter for atrial fibrillation, using endoscopic optical visualization. Closely comparable to LuxMed's optical tissue interrogation approach and CEO Amirana sits on its board.
• CathRx: Australian developer of diagnostic and ablation catheters for cardiac EP, including pulsed field ablation. CEO Amirana serves on its board, making it a directly relevant peer in the EP catheter space.
• AtriCure: Specialist in cardiac surgical ablation (cryo and RF) and left atrial appendage management. Comparable as an EP-focused ablation device company, although focused on surgical rather than catheter-based ablation.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/luxmed-systems-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LuxMed